Bio Green Med Solution, Inc.
No SEC Form 4 filings for $BGMS in the last 30 days.
See all $BGMS insider activity →Bio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 BIO GREEN MED SOLUTION Reports SECOND quarter financial results and provides business update KUALA LUMPUR, MALAYSIA, August 12, 2026 – Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged pri
Bio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001130166 0001130166 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2026 D
Bio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 10, 2026 (the “Effective Date”), between Bio Green Med Solution, Inc., a Delaware corporation (the “ Company ”), and _______, an ind
Over the past 7 days, alphai's AI scored 1 news story mentioning BGMS (Bio Green Med Solution, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BGMS coverage spans financial news, corporate actions and earnings.
The filing adds concrete capital structure and cash runway details, plus a potential ownership shift via the FNRG exchange, which can affect dilution and control expectations.
Routine corporate governance outcomes; limited direct impact on near-term fundamentals, but confirms board/auditor continuity.
The filing signals a new capital raise via an unregistered securities purchase agreement, which can be dilutive and may pressure near-term valuation.
M&A headline is the direct catalyst for today’s outsized move; near-term focus shifts to deal mechanics, approvals, and SEC registration timing.
Bio Green Med Solution Inc. reported a Q4 net income of -$611 Thousand. This brief announcement from Refinitiv provides a key financial update for the company. The article focuses solely on this financial figure without further elaboration.
alphai scores every news story that mentions BGMS with an AI model for sentiment and relevance, and aggregates insider trades from Bio Green Med Solution, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 BIO GREEN MED SOLUTION Reports SECOND quarter financial results and provides business update KUALA LUMPUR, MALAYSIA, August 12, 2026 – Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged pri
4 min readBio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001130166 0001130166 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2026 D
2 min readBio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 10, 2026 (the “Effective Date”), between Bio Green Med Solution, Inc., a Delaware corporation (the “ Company ”), and _______, an ind
3 min readBio Green Med Solution (NASDAQ:BGMS) shares rose about 123% to $2.35 after it signed an all-stock business combination agreement with Malaysia-based Future NRG. Future NRG will become a wholly owned BGMS subsidiary; the combined firm is expected to trade on Nasdaq under BGMS, led by Datuk Dr. Doris Wong Sing Ee. The deal is expected to close in Q4 2026, pending shareholder approval and SEC registration.
4 min readBio Green Med Solution Inc. reported a Q4 net income of -$611 Thousand. This brief announcement from Refinitiv provides a key financial update for the company. The article focuses solely on this financial figure without further elaboration.
1 min readOng Yee Lung has filed an amendment to Schedule 13G/A for Bio Green Med Solution, Inc. (BGMS), reporting zero beneficial ownership of the company's common stock. This filing indicates that Ong Yee Lung holds 0 shares, representing 0% of BGMS, and has no voting or dispositive power over any shares. The amendment, dated March 13, 2026, is considered to have a neutral sentiment and moderate impact on corporate governance.
2 min readThis article highlights 12 healthcare stocks experiencing significant price movements during Friday's intraday trading session. It details both the top gainers, such as Ironwood Pharmaceuticals and Shuttle Pharmaceuticals, and the top losers, including Outlook Therapeutics and Bio Green Med Solution, along with their respective percentage changes and market capitalizations.
4 min readKUALA LUMPUR, Malaysia, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Bio Green Med Solution, Inc. ( NASDAQ: BGMS, NASDAQ: BGMSP. "BGMS" or the "Company" ( formerly Cyclacel Pharmaceuticals, Inc. ) ) , a diversified company engaged primarily in the provision of fire safety protection and distribution ...
4 min read
